Counteracting Age-related Loss of Skeletal Muscle Mass

Summary

Up to approximately 205 (dependent on drop-out rate) healthy elderly individuals (at least 65 years old) are recruited as subjects.

Upon inclusion, each individual will be randomized into one of the five groups stratified according to gender (M/F) and 30s chair stand (\<16 OR ≥16). The five groups are: Heavy Resistance Training (N=30-35), Light Intensity Training (N=30-35), Protein Whey (N=40-50), Protein Collagen (N=40-50) and Carbohydrate (N=30-35). The individuals randomized into one of the supplementation groups (Protein Whey, Protein Collagen or Carbohydrate) will be blinded to the supplement content.

Assessments will be performed at Baseline (before intervention start), and after 6 and 12 months of intervention and again at 18 months (after 6 months of follow up).

The primary outcome is change in quadriceps muscle cross sectional area from Baseline to 12 months of intervention.

The primary hypothesis is that by applying the intension-to-treat analysis, the Light Intensity Training group will increase quadriceps muscle cross sectional area just as much as the Heavy Resistance Training group. The two training groups will gain more muscle mass than the Protein Whey group, which will gain more than the Protein Collagen and the Carbohydrate groups that will loose quadriceps muscle cross sectional areas.

Conditions

• Sarcopenia
• Muscle Loss

Interventions

PROCEDURE

Heavy Resistance Training

Supervised Heavy Resistance Training three times weekly for 52 weeks.

PROCEDURE

Light Intensity Training

Home-based Light Intensity Training three-five times weekly for 52 weeks.

DIETARY_SUPPLEMENT

Protein Whey

Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.

DIETARY_SUPPLEMENT

Protein Collagen

Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.

DIETARY_SUPPLEMENT

Carbohydrate

Two daily 30g carbohydrate supplementations for 52 weeks.

Sponsors & Collaborators

• University of Copenhagen

  collaborator OTHER

• Arla Foods

  collaborator INDUSTRY

• Bispebjerg Hospital

  lead OTHER

Principal Investigators

• Rasmus Bechshøft, Ph.d. stud · Bispebjerg Hospital

• Lars Holm, Assoc. prof. · Bispebjerg Hospital

• Michael Kjaer, MD, Proff. · Bispebjerg Hospital

• Søren Reitelseder, Ph.d. · Bispebjerg Hospital

• Jacob Bülow, MD PhD stud · Bispebjerg Hospital

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2014-01-10

Primary Completion

2019-06-30

Completion

2019-08-31

Countries

• Denmark